tldrdailynews.com logo
Tag

Nuvalent

All articles tagged with #nuvalent

GSK to buy Nuvalent for $10.6B, adding a multi-asset NSCLC portfolio
business1 month ago

GSK to buy Nuvalent for $10.6B, adding a multi-asset NSCLC portfolio

GSK will acquire Nuvalent for $10.6 billion in cash ($124 per share), gaining three NSCLC programs—zidesamtinib (ROS1) and neladalkib (ALK) as late-stage, potentially best-in-class therapies plus NVL-330 (HER2) and a preclinical portfolio—along with a platform for lung-cancer expansion. The deal, expected to close after regulatory approvals in 2026, is designed to be revenue- accretive from 2027 and-core EPS accretive by 2029 (including synergies and reprioritisation), financed largely by debt and cash with no expected rating impact and maintaining GSK’s dividend policy.

via GSK|
#alk#business#gsk
business1 month ago

Nuvalent soars on GSK deal as Smucker beats, SailPoint slides; chips rebound in premarket

Premarket movers include Nuvalent jumping about 39% after GSK agreed to acquire it for $10.6 billion; J.M. Smucker rose about 3.5% after Q4 results beat estimates; SailPoint fell more than 12% on weaker full-year guidance despite earnings beating expectations; Alibaba edged up roughly 0.9% as the Pentagon added Chinese firms to a military list; Vail Resorts dropped about 4.9% after soft Q3 results, while Micron and Qualcomm helped drive a chip stock rebound in premarket trading.

via CNBC|
#alibaba#business#gsk
Nuvalent Raises $300M in Public Stock Offering
biotechpharmaceuticals2 years ago

Nuvalent Raises $300M in Public Stock Offering

Cancer biotech company Nuvalent has announced a $300 million public offering of its common stock following positive Phase I results for its ALK-selective tyrosine kinase inhibitor candidate, NVL-655, in ALK-positive non-small cell lung cancer patients, with a 39% objective response rate observed in evaluable patients.

via Endpoints News|
#alk-selective-tyrosine-kinase-inhibitor#biotechpharmaceuticals#cancer-biotech